A European technology acquirer had identified a mid-size Israeli software target. The deal represented a significant market entry opportunity. But competition clearance requirements under Israeli law – combined with a complex closing conditions regime – threatened to derail the transaction before it reached signing.
M&A transactions in Israel require competition clearance from the Rashut HaTachrut (Israel Competition Authority) where prescribed turnover thresholds are met. The primary transaction document is a share purchase agreement (SPA) governed by Israeli commercial legislation, supported by a structured due diligence process. Closing conditions, representations and warranties, and regulatory approvals must all be sequenced correctly to protect the acquirer's position.
This case study examines how the transaction was structured, the complications encountered during the regulatory clearance phase, and the transferable lessons for cross-border acquirers approaching the Israeli market.
Client profile and the challenge at hand
The client was a European holding company with operations across three jurisdictions. It had no prior experience with Israeli M&A. The target was a profitable Israeli technology business with a dominant position in a niche B2B segment.
The challenge was threefold. First, the combined market shares triggered a mandatory filing obligation under Israeli competition legislation. Second, the target's due diligence materials revealed undisclosed regulatory correspondence that required careful handling in the SPA. Third, the client's board had set a fixed closing deadline tied to its own financing structure. Any delay in competition clearance would trigger a break fee obligation on the acquirer's side.
The client engaged Ferraz & Whitmore to coordinate the cross-border legal strategy, working alongside Israeli counsel on local regulatory filings. Our role covered SPA structuring, due diligence review from a cross-border perspective, and closing conditions architecture. For clients seeking a broader overview of deal execution in this market, our M&A advisory services in Israel set out the full transactional context.
Legal strategy: sequencing clearance and closing conditions
The core strategic decision was whether to sign and then file for competition clearance – or to condition signing itself on a pre-clearance commitment from the Israel Competition Authority. Each path carried distinct risks.
Signing first and filing post-execution is the more common approach in Israeli practice. It allows the parties to lock in commercial terms. But it exposes the acquirer to a protracted clearance period during which either party may seek to renegotiate or exit. Given the client's financing deadline, this risk was material.
The team structured a hybrid approach. The SPA was executed with a long-stop date set generously beyond the expected clearance timeline. Closing conditions were drafted to include a specific competition clearance condition, with carefully negotiated termination rights if clearance was refused or materially conditioned. The representations and warranties section addressed the undisclosed regulatory correspondence directly, with a specific indemnity carve-out and an escrow mechanism to cover potential post-closing liability.
The due diligence process had already flagged that the target held contracts with two state-adjacent entities. Under Israeli corporate legislation and sector-specific rules, those contracts required a separate consent process. That consent obligation was embedded as an additional closing condition, with a defined cure period. Engaging a law firm in Israel with regulatory experience was essential to mapping these consent requirements accurately.
Key milestones and complications encountered
The filing to the Israel Competition Authority was submitted within two weeks of signing. The initial review period under Israeli competition legislation ran for approximately 30 days. The Authority then issued a request for supplementary information – a common occurrence in transactions involving market-concentrated targets.
The supplementary information request extended the effective review period by several weeks. This compression against the long-stop date created pressure. The client considered invoking the SPA's material adverse change provisions to justify a price adjustment. The team advised against this course. The regulatory delay was foreseeable and explicitly carved out of the MAC definition in the SPA. Invoking it would have been contractually unsound and would have damaged trust with the target at a sensitive stage.
Instead, the parties agreed a short written extension to the long-stop date. This was documented as a formal amendment to the SPA. The consent process for the state-adjacent contracts ran in parallel and completed on schedule. The Israel Competition Authority ultimately granted clearance subject to a behavioural remedy – a standard condition in technology sector transactions with vertical integration characteristics. Clients working through related corporate structuring questions in Israel will find our corporate law advisory for Israel a useful reference for post-closing integration planning.
Closing occurred approximately 14 weeks after signing. The escrow mechanism for the regulatory correspondence indemnity remained in place for the contractually agreed post-closing period.
For acquirers interested in how similar regulatory conditions play out in a different high-growth market context, our case study on M&A transactions in the UAE offers a directly comparable cross-border perspective.
To discuss how a similar strategy could apply to your acquisition in Israel, contact us at info@ferrazwhitmore.com.
Three transferable lessons for cross-border acquirers
Lesson 1: Map regulatory consent obligations before SPA execution, not after. The state-adjacent contract consents in this matter were identified late in due diligence. Had they emerged only after signing, they would have constituted a material gap in the closing conditions regime. In Israeli M&A, due diligence must cover not only standard corporate and financial matters but also sector-specific licensing and consent requirements that may sit outside the main company structure.
Lesson 2: Draft closing conditions and termination rights with regulatory delay in mind. A long-stop date that does not account for a realistic competition clearance timeline is one of the most common structural errors in cross-border Israeli deals. The Israel Competition Authority's review process routinely involves supplementary information requests. The SPA must reflect that reality. Termination rights should be precisely calibrated – not open-ended – to avoid strategic misuse by either party.
Lesson 3: Use the representations and warranties regime to address known risk, not to ignore it. The undisclosed regulatory correspondence in this matter could have become a post-closing dispute of significant cost. By identifying it in due diligence, addressing it directly in the representations and warranties, and backing it with a targeted indemnity and escrow, the parties converted an open-ended risk into a quantified, time-limited obligation. That approach protects both buyer and seller and reduces the probability of post-closing litigation.
About Ferraz & Whitmore
Ferraz & Whitmore is an international law firm based in Lisbon, advising business clients across 46 jurisdictions. Our team combines Portuguese civil law expertise with English common law tradition to deliver cross-border legal solutions in M&A transactions, competition clearance, and corporate structuring. In Israel and across Asia-Pacific and Middle Eastern markets, we support international acquirers from initial due diligence through to post-closing integration. Our M&A practice spans both civil law and common law systems, with practitioners experienced in cross-border share purchase agreement negotiation, closing conditions architecture, and regulatory filings before competition authorities. As a law firm advising clients on Israeli market entry, we work alongside trusted local counsel to ensure regulatory and commercial requirements are handled in full. To discuss your acquisition or investment in Israel, contact us at info@ferrazwhitmore.com.
Disclaimer: This publication is provided for informational purposes only and does not constitute legal advice. The information herein should not be relied upon as a substitute for professional legal counsel tailored to your specific circumstances. Ferraz & Whitmore assumes no liability for actions taken or not taken based on the contents of this material. For advice regarding your particular situation, please contact info@ferrazwhitmore.com.